Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

2018 Cotellic (cobimetinib; Exelixis/Roche) Drug Analysis - ResearchAndMarkets.com

Research and Markets
Posted on: 20 Feb 18

The "Drug analysis: Cotellic" drug pipelines has been added to ResearchAndMarkets.com's offering.

Cotellic (cobimetinib; Exelixis/Roche) is a selective inhibitor of mitogen-activated protein kinase (MEK), a serine/threonine kinase that is a component of the RAS/RAF/MEK/ERK pathway. Cotellic specifically binds to and inhibits the catalytic activity of MEK, resulting in inhibition of extracellular signal-related kinase 2 (ERK2) phosphorylation. In preclinical studies, oral dosing of Cotellic resulted in potent and sustained inhibition of MEK in RAS or BRAF mutant tumor models. Cotellic is being developed by Roche under a collaboration agreement with Exelixis.

Key Topics Covered:

Product Profiles

Cotellic: Colorectal cancer (CRC)

Cotellic: Melanoma

List of Figures

Figure 1: Cotellic for colorectal cancer - SWOT analysis

Figure 2: Drug assessment summary of Cotellic for colorectal cancer

Figure 3: Drug assessment summary of Cotellic for colorectal cancer

Figure 4: Cotellic sales for colorectal cancer across the US and five major EU markets, by country, 2016-25

Figure 5: Cotellic in melanoma - SWOT analysis

Figure 6: Drug assessment summary of Cotellic for melanoma

Figure 7: Drug assessment summary of Cotellic for melanoma

List of Tables

Table 1: Cotellic drug profile

Table 2: Cotellic Phase III trial in colorectal cancer

Table 3: Cotellic early-phase data in colorectal cancer

Table 4: Cotellic sales for colorectal cancer across the US and five major EU markets, by country ($m), 2016-25

Table 5: Patients treated with Cotellic in the US and five major EU markets, by country, 2016-25

Table 6: Cotellic drug profile

Table 7: Cotellic pivotal trial data in melanoma

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/xvv8dk/2018_cotellic?w=4

View source version on businesswire.com: http://www.businesswire.com/news/home/20180220006271/en/

Business Wire
www.businesswire.com

Last updated on: 20/02/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.